The flgr 242 peptide is an HGF/c-Met pathway research compound evaluated in preclinical models for its role in hepatocyte growth factor signaling, synaptogenesis, and neuronal-network plasticity. In comparative laboratory studies, researchers measure its receptor binding affinity and structural stability against established analogs like Dihexa. PX1 Research provides USA-manufactured, analytical-grade FLGR 242 verified by third-party HPLC and mass spectrometry for in vitro research.
The flgr 242 peptide is an HGF/c-Met pathway research compound evaluated in preclinical models for its role in hepatocyte growth factor signaling, synaptogenesis, and neuronal-network plasticity. In comparative laboratory studies, researchers measure its receptor binding affinity and structural stability against established analogs like Dihexa. PX1 Research provides USA-manufactured, analytical-grade FLGR 242 verified by third-party HPLC and mass spectrometry for in vitro research.
The flgr 242 peptide has emerged as an important tool compound within neurobiology and cell signaling research. Designed to target and modulate the hepatocyte growth factor (HGF) and its receptor tyrosine kinase, c-Met, FLGR-242 provides investigator teams with a molecular probe to study downstream intracellular cascades. In preclinical models, the HGF/c-Met axis plays a central role in cell survival, tissue regeneration, dendritic spinogenesis, and functional synaptic rearrangement.
While traditional research focused primarily on whole-protein growth factors, small synthetic peptides like FLGR-242 and Dihexa offer distinct experimental advantages. These small-molecule peptidomimetics demonstrate higher enzymatic stability in culture, defined molecular weights, and precise stoichiometry during in vitro screening. Consequently, laboratories utilize the flgr 242 peptide to decipher the exact structural motifs required to potentiate c-Met autophosphorylation without triggering uncontrolled cellular proliferation.
Hepatocyte growth factor (HGF) is a multifunctional heterodimeric cytokine that binds to the extracellular domain of the c-Met receptor. Upon ligand binding, c-Met undergoes homodimerization, activating its intrinsic tyrosine kinase domain. This autophosphorylation event creates docking sites for downstream signaling adaptors, initiating the Ras/MAPK, PI3K/Akt, and STAT3 pathways. In the central nervous system, these pathways govern structural plasticity, axonal guidance, and neuroprotection.
Preclinical studies suggest that the flgr 242 peptide acts as a high-affinity ligand or positive allosteric modulator of the HGF/c-Met complex. Rather than replacing native growth factors entirely, FLGR-242 appears to stabilize the active receptor conformation or facilitate HGF dimerization. In vitro assays using primary hippocampal neurons demonstrate that activation of c-Met via HGF-modulating compounds accelerates the expression of postsynaptic density protein 95 (PSD-95) and synaptophysin, fundamental markers of functional synapse formation.
When evaluating compounds designed to engage the HGF/c-Met system, laboratory investigators frequently compare Dihexa and the flgr 242 peptide. Dihexa (hexanoic-Tyr-Ile-6-aminohexanoic amide) is an established N-terminal substituted peptide derivative known for its nanomolar affinity for HGF. In contrast, FLGR-242 incorporates distinct structural modifications intended to alter half-life, solubility, and conformational flexibility within aqueous assay buffers.
Comparative in vitro binding assays indicate that both compounds possess potent HGF-potentiating activity, yet they exhibit subtle differences in kinetic profiles. Dihexa exhibits robust resistance to proteolytic cleavage, making it a benchmark standard for long-term neuronal culture experiments. However, FLGR-242 is frequently selected for assays requiring specific interaction kinetics or alternative solubility parameters. Researchers exploring neuroplasticity pathways often evaluate both compounds side-by-side to map receptor binding kinetics across different cell types within our broader research library hub.
Synaptogenesis—the formation of new synaptic connections between neurons—is a primary focus of neurodegenerative and cognitive research. Preclinical animal models and organotypic slice cultures have shown that modulating HGF/c-Met signaling with peptides like FLGR-242 increases dendritic spine density. Dendritic spines serve as the postsynaptic receptive sites for the majority of excitatory synapses, and changes in their morphology correlate directly with synaptic strength and long-term potentiation (LTP).
In vitro data indicate that incubation of primary neuronal cultures with the flgr 242 peptide leads to a rapid extension of neuritic processes and enhanced dendritic arborization. These structural changes are mediated through PI3K-dependent remodeling of the actin cytoskeleton. By utilizing analytical-grade peptides, researchers can accurately measure baseline signaling events, receptor internalization rates, and downstream gene transcription related to neuroplasticity without confounding background variables.
To characterize the pharmacodynamics of the flgr 242 peptide, research facilities employ surface plasmon resonance (SPR), isothermal titration calorimetry (ITC), and Western blot autophosphorylation assays. SPR analysis permits real-time tracking of association (ka) and dissociation (kd) constants between FLGR-242 and immobilized HGF domains, yielding precise equilibrium dissociation constants (KD).
Furthermore, cellular activation assays measure c-Met phosphorylation at specific tyrosine residues (Tyr1234/1235). Experimental protocols involve serum-starving neural or epithelial cell lines before exposure to graded concentrations of FLGR-242. Western blot visualization confirms whether signal transduction occurs via direct receptor phosphorylation or secondary cross-talk with adjacent receptor tyrosine kinases. For extended screening workflows, laboratory directors often cross-reference these findings with other neuroplasticity research compounds.
Assay reproducibility in cellular signaling studies requires rigorous peptide purity and lot-to-lot consistency. Unpurified peptide synthesis byproducts—such as truncated sequences or residual TFA salts—can induce non-specific cytotoxic effects in sensitive cell cultures, skewing signaling data. PX1 Research enforces strict quality assurance protocols for every batch of flgr 242 peptide.
All compounds synthesized in our GMP-compliant facilities undergo dual validation via Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) and Electrospray Ionization Mass Spectrometry (ESI-MS) within an ISO 17025 accredited laboratory. Purity levels are consistently verified at ≥98.0%. Additionally, because bacterial lipopolysaccharides (LPS) can trigger microglial activation and mask HGF-mediated inflammatory responses, PX1 performs quantitative chromogenic LAL endotoxin testing to guarantee endotoxin content remains strictly below <0.01 EU/mg.
The flgr 242 peptide is supplied as a lyophilized (freeze-dried) cake or powder to ensure maximal chemical stability during transit and storage. To preserve sequence integrity and prevent aggregation, research personnel must follow strict reconstitution protocols in a sterile laminar flow hood.
Lyophilized vials should be allowed to equilibrate to room temperature prior to reconstitution to minimize moisture condensation. The choice of solvent depends on the planned assay system. While FLGR-242 dissolves readily in sterile bacteriostatic water or phosphate-buffered saline (PBS, pH 7.4), compounds targeting hydrophobic receptor pockets may require initial solubilization in molecular biology grade DMSO (dimethyl sulfoxide) before dilution into aqueous cell culture media. Stock solutions should be aliquoted into single-use polypropylene tubes and stored at -80°C to prevent degradation from repeated freeze-thaw cycles.
Within the broader landscape of neuroplasticity and cognitive research, the flgr 242 peptide belongs to a specialized class of receptor-modulating ligands. When designing comprehensive screening panels, laboratories frequently compare FLGR-242 against established compounds such as Dihexa, N-Acetyl Semax Amidate, and PE-22-28.
While Dihexa and FLGR-242 act directly within the HGF/c-Met receptor architecture to promote dendritic spinogenesis, peptides like N-Acetyl Semax Amidate modulate BDNF/TrkB expression pathways, and PE-22-28 targets the TREK-1 potassium channel system. Evaluating these distinct biochemical axes allows researchers to map complementary mechanisms of action across diverse central nervous system targets. Accessing high-purity standards across all peptide classes ensures consistent, publishable results.
PX1 Research operates dedicated manufacturing and logistics facilities within the USA, ensuring complete control over compound synthesis, analytical testing, and cold-chain packaging. By maintaining ISO 17025 compliant laboratory operations, PX1 provides verifiable Certificate of Analysis (COA) documents with every single lot.
Orders placed by academic institutions, pharmaceutical laboratories, and independent research groups are processed with same-day shipping (Monday through Friday) originating from our distribution centers in California and Arizona. Secure protective packaging protects temperature-sensitive peptides like the flgr 242 peptide during transport, preserving structural integrity from our facilities directly to your benchtop. For large-scale synthesis requirements, explore our wholesale lab account options.
What is the flgr 242 peptide?
The flgr 242 peptide is a synthetic oligopeptide research compound designed to interact with the hepatocyte growth factor (HGF) signaling pathway and activate c-Met receptor tyrosine kinases in preclinical in vitro models.
How does the flgr 242 peptide interact with the HGF/c-Met receptor axis?
Preclinical data indicate FLGR-242 binds to HGF or the c-Met extracellular domain, potentiating ligand-induced receptor dimerization and downstream autophosphorylation of cascades like PI3K/Akt and Ras/MAPK.
How does FLGR 242 compare to Dihexa in preclinical assays?
Both compounds target HGF/c-Met signaling to encourage synaptogenesis; however, Dihexa features an N-terminal hexanoyl substitution engineered for extreme enzymatic stability, whereas FLGR-242 presents distinct structural parameters for comparative kinetic and solubility studies.
What purity level is guaranteed for FLGR 242 peptide from PX1 Research?
PX1 Research guarantees a minimum chemical purity of ≥98.0% for FLGR 242 peptide, verified via high-performance liquid chromatography (RP-HPLC) and mass spectrometry (ESI-MS).
Is a Certificate of Analysis (COA) provided with FLGR 242 peptide orders?
Yes. Every lot of FLGR 242 peptide includes an accessible, lot-specific Certificate of Analysis detailing exact HPLC purity curves, mass spectrometry identity validation, and endotoxin assay results.
What are the endotoxin limits for PX1 Research peptides?
PX1 Research enforces strict endotoxin screening using chromogenic LAL assays, ensuring endotoxin levels remain below <0.01 EU/mg to eliminate non-specific inflammatory artifacts in cell culture.
How should FLGR 242 peptide be reconstituted for laboratory use?
Reconstitution should occur in a sterile environment using sterile bacteriostatic water, PBS (pH 7.4), or a low concentration of DMSO depending on assay requirements. Stock solutions should be aliquoted and frozen at -80°C.
Is FLGR 242 peptide approved for human administration or clinical use?
No. The FLGR 242 peptide is strictly manufactured and sold for laboratory research use only (in vitro and preclinical models). It is not intended for human or animal diagnostic, therapeutic, or clinical applications.
Where is PX1 Research peptide manufacturing and shipping located?
All PX1 Research compounds are manufactured in USA-based, GMP-compliant facilities. Products ship same-day (Monday through Friday) from our fulfillment centers in California and Arizona.
How can research institutions purchase FLGR 242 peptide in bulk quantities?
Institutions requiring custom synthesis or bulk quantities can apply for a [wholesale lab account](/wholesale) through the PX1 Research platform to access institutional pricing and dedicated account management.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.